期刊
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 20, 期 10, 页码 3103-3106出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2010.03.108
关键词
Positron emission tomography; Vasopressin; SSR149415; Carbon-11
资金
- Brookhaven National Laboratory with the U. S. Department of Energy [DE-AC02-98CH10886]
- Study Foundation of the German People
SSR149415 was the first non-peptide vasopressin-(V-1b) receptor antagonist reported. It has been used to probe the role of V-1b receptors in animal models of depression, aggression, and stress-anxiety, and was progressed to clinical trials for the treatment of depression. Due to the interest in V-1b receptors as a therapeutic target and the growing use of SSR149415 in preclinical research, we developed a method to label SSR145419 with carbon-11 and have studied its pharmacokinetics in non-human primates using positron emission tomography. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据